Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
Blood|March 15, 2003
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphomaSarah H Walsh, Mia Thorsélius, Anna Johnson, et al.
Blood|December 21, 2021
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphomaLeo Meriranta, Amjad Alkodsi, Annika Pasanen, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Hemasphere|February 20, 2020
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network StudyLucia Morello, Sara Rattotti, Laura Giordano, et al.
Blood|December 25, 2009
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)Christian H Geisler, Arne Kolstad, Anna Laurell, et al.
Blood|August 19, 2017
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapyChristian W Eskelund, Christina Dahl, Jakob W Hansen, et al.
American Journal of Hematology|May 26, 2016
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaborationChan Y Cheah, Paul J Bröckelmann, Dai Chihara, et al.
American Journal of Hematology|January 2, 2023
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology groupAhmed Ludvigsen Al-Mashhadi, Henrik Cederleuf, Rasmus Kuhr Jensen, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Haematologica|October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
Pageof 17